Overview

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Status:
Recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Fingolimod Hydrochloride
Ofatumumab
Siponimod